pDONR223-PDK1 Citations (4)

Originally described in: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.
Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL, Sellers WR, Schlegel R, Wargo JA, Hahn WC, Garraway LA Nature. 2010 Dec 16;468(7326):968-72. doi: 10.1038/nature09627 PubMed Journal

---

Articles Citing pDONR223-PDK1

Articles
KDM4A Coactivates E2F1 to Regulate the PDK-Dependent Metabolic Switch between Mitochondrial Oxidation and Glycolysis. Wang LY, Hung CL, Chen YR, Yang JC, Wang J, Campbell M, Izumiya Y, Chen HW, Wang WC, Ann DK, Kung HJ. Cell Rep. 2016 Sep 13;16(11):3016-27. doi: 10.1016/j.celrep.2016.08.018. PubMed
Synthesis and biological evaluation of (R)-3,3,3-trifluoro-2-hydroxy-2-methylpropionamides as pyruvate dehydrogenase kinase 1 (PDK1) inhibitors to reduce the growth of cancer cells. Zhang SL, Zhang W, Yang Z, Hu X, Tam KY. Eur J Pharm Sci. 2017 Mar 24. pii: S0928-0987(17)30165-3. doi: 10.1016/j.ejps.2017.03.030. PubMed
Phenyl butyrate inhibits pyruvate dehydrogenase kinase 1 and contributes to its anti-cancer effect. Zhang W, Zhang SL, Hu X, Tam KY. Eur J Pharm Sci. 2017 Apr 25. pii: S0928-0987(17)30212-9. doi: 10.1016/j.ejps.2017.04.018. PubMed
Identification of Novel Pyruvate Dehydrogenase Kinase 1 (PDK1) Inhibitors by Kinase Activity-Based High-Throughput Screening for Anticancer Therapeutics. Zhang W, Hu X, Chakravarty H, Yang Z, Tam KY. ACS Comb Sci. 2018 Nov 12;20(11):660-671. doi: 10.1021/acscombsci.8b00104. Epub 2018 Oct 23. PubMed

If you have published an article using this material, please email us at to have your article added to this page.